Therapeutic blockade of Foxp3 in experimental breast cancer models

MORENO AYALA, MARIELA A.; GOTTARDO, MARÍA FLORENCIA; IMSEN, MERCEDES; ASAD, ANTONELA SOFIA; BAL DE KIER JOFFÉ, ELISA; NOELIA CASARES; JUAN JOSE LASARTE; SEILICOVICH, ADRIANA; CANDOLFI, MARIANELA

BREAST CANCER RESEARCH AND TREATMENT

SPRINGER

Lugar: Berlin; Año: 2017 p. 393 - 405

0167-6806

Purpose. Regulatory T cells (Tregs) impair the clinical benefit of cancer immunotherapy. To optimize the antitumor efficacy of therapeutic dendritic cell (DC) vaccines, we aimed to inhibit Foxp3, a transcription factor required for Treg function. Methods. Mice bearing established syngeneic LM3 and 4T1 breast tumors were treated with antitumor DC vaccines and a synthetic peptide (P60) that has been shown to inhibit Foxp3. Results. Treatment with P60 improved the therapeutic efficacy of DC vaccines in these experimental models. In addition, monotherapy with P60 inhibited tumor growth in immunocompetent as well as in immuno-compromised animals bearing established tumors. We found expression of Foxp3 in human and murine breast tumor cells. P60 inhibited IL-10 secretion in breast cancer cells that expressed Foxp3. Conclusions. Our results suggest that Foxp3 blockade improves the therapeutic efficacy of DC vaccines by inhibition of Tregs and through a direct antitumor effect. This strategy could prove useful to neutralize the immunosuppressive microenvironment and boost antitumor immunity in breast cancer.